Treatment of Acute Myeloblastic Leukaemia with RP 22050

Fourty-four patients with acute myeloblastic leukaemia were treated with RP 22050, a new, semisynthetic derivative of daunorubicin. Complete remissions were achieved in 20 patients (45%). The median dose given was 23 mg/kg. The toxicity of RP 22050 is mainly haematological. Resistance rather than de...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Jacquillat, C., Weil, M., Gemon, M. F., Izrael, V., Schaison, G., Boiron, M., Bernard, Jean
Médium: Artigo
Jazyk:Inglês
Vydáno: 1972
Témata:
Papers and Originals
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC1786703/
https://ncbi.nlm.nih.gov/pubmed/4510816
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky